The stock is likely to react positively to the strong earnings beat and raised guidance. Traders should watch for continued execution on the Specialty segment growth and whether the company can maintain momentum in Affordable Medicines, which saw a slight Q4 decline. The debt refinancing completed in August 2025 (noted in the filing) may have improved the balance sheet, which could support future growth initiatives.
Price Chart
Executive Summary
Amneal Pharmaceuticals reported strong Q4 and full-year 2025 results, with revenue up 11% and 8% YoY respectively, and a return to profitability. The company also provided 2026 guidance that exceeds 2025 results, signaling continued growth. This positive performance is driven by strong Specialty segment growth and new product launches.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $814 million (11% YoY growth), GAAP net income: $35 million (vs. $31M loss in Q4 2024)
- Full-year 2025 revenue: $3.02 billion (8% YoY growth), GAAP net income: $72 million (vs. $117M loss in 2024)
- 2026 guidance: $3.05-$3.15 billion revenue, $720-$760 million Adjusted EBITDA, $0.93-$1.03 Adjusted EPS
- Specialty segment revenue grew 38% in Q4 and 19% for the full year, driven by CREXONT and UNITHROID
- Company launched new branded product BREKIYA autoinjector and first two inhalation products
Financial Impact
Revenue increased $226 million YoY to $3.02 billion, with Adjusted EBITDA up $61 million to $688 million. 2026 guidance projects revenue growth to $3.15B and Adjusted EBITDA to $760M.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Specialty | $528.5M | +18.6% |
| Affordable Medicines | $1.7B | +3.6% |
| AvKARE | $744.7M | +12.3% |
Risk Factors
- Affordable Medicines segment revenue declined 1% in Q4 2025 due to timing of key product launches
- Company has significant long-term debt ($2.57 billion) which could limit financial flexibility
- Guidance assumes successful execution of new product launches and favorable market conditions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001723128-26-000008 |
| Document: amrx-20260227.htm | 0001723128-26-000008 |
| Document: 0001723128-26-000008-index-headers.html | 0001723128-26-000008 |
| Document: 0001723128-26-000008-index.html | 0001723128-26-000008 |
| Document: 0001723128-26-000008.txt | 0001723128-26-000008 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K/A | $20.38 | awaiting T+60 | — | $21.24 (+4.20%) |
Sep 18, 2026 5w ago | Press Release | $20.16 | awaiting T+60 | — | $21.24 (+5.33%) |
Aug 16, 2026 10w ago | Institutional Cluster | $18.42 | awaiting T+60 | — | $21.24 (+15.28%) |
Aug 14, 2026 10w ago | Insider Cluster | $18.42 | awaiting T+60 | — | $21.24 (+15.28%) |
Aug 13, 2026 10w ago | Insider Cluster | $18.15 | awaiting T+60 | — | $21.24 (−17.00%) |
Aug 10, 2026 11w ago | 8-K | $17.10 | awaiting T+60 | — | $21.24 (+24.18%) |
Jul 30, 2026 12w ago | DEFA14A | $18.50 $20.38 | ▲ +10.16% | ▲ +7.70% | $21.24 (+14.78%) |
Jul 17, 2026 14w ago | Press Release | $17.85 $20.03 | ▲ +12.21% | ▲ +7.53% | $21.24 (+18.96%) |
Jun 29, 2026 17w ago | DEFM14A | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.24 (+22.82%) |
Jun 29, 2026 17w ago | Press Release | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.24 (+22.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers